Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods

Tools

Mitchell, Anneka and Watson, Margaret C and Welsh, Tomas J and McGrogan, Anita (2025) Safety and effectiveness of anticoagulation therapy in older people with atrial fibrillation during exposed and unexposed treatment periods. Heart. ISSN 1468-201X (https://doi.org/10.1136/heartjnl-2024-324763)

[thumbnail of heartjnl-2024-Safety-and-effectiveness-of-anticoagulation-therapy-in-older-people-with-atrial-fibrillation]
Preview
 Text. Filename: heartjnl-2024-Safety-and-effectiveness-of-anticoagulation-therapy-in-older-people-with-atrial-fibrillation.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Background: Anticoagulation therapy reduces stroke risk in patients with atrial fibrillation (AF), but it is often underused in older populations due to concerns about bleeding. This study aimed to compare the safety and effectiveness of anticoagulation during periods of exposure and non-exposure and across different anticoagulants in people with AF aged ≥75 years. Methods: Using UK primary care data from the Clinical Practice Research Datalink (2013–2017), a retrospective cohort study was conducted on patients newly prescribed oral anticoagulants (warfarin or direct oral anticoagulants). Exposure to anticoagulation was mapped using prescription data. Cox regression models were used to estimate adjusted HRs for stroke, bleeding, myocardial infarction, and death during periods of exposure and non-exposure and for different anticoagulants. Results: Among 20 167 patients (median age 81 years), non-exposure to anticoagulation was associated with higher risks of stroke (HR 3.07, 95% CI 2.39 to 3.93), myocardial infarction (HR 1.85, 95% CI 1.34 to 2.56) and death (HR 2.87, 95% CI 2.63 to 3.12) compared with exposure. Compared with warfarin, apixaban was associated with lower risks of non-major bleeding (HR 0.73, 95% CI 0.64 to 0.85), whereas rivaroxaban was associated with higher risks of major (HR 1.33, 95% CI 1.15 to 1.55) and non-major (HR 1.29, 95% CI 1.16 to 1.44) bleeding. Conclusions: Non-exposure to anticoagulation increases the risks of stroke, myocardial infarction and death in older patients with AF. Clinicians should carefully weigh the risks of discontinuing anticoagulation and provide shared decision-making support to patients, especially when considering deprescription.

ORCID iDs

Mitchell, Anneka, Watson, Margaret C ORCID logoORCID: https://orcid.org/0000-0002-8198-9273, Welsh, Tomas J and McGrogan, Anita;
CORE (COnnecting REpositories)